Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Eisai China to Repack and Sell STADA Diabetes Drug

publication date: Aug 4, 2008

Eisai China, Inc. (ECI), the wholly owned China subsidiary of Japan pharma Eisai Co., will repack and sell Alpha-Lipon 300 STADA®, an alpha-lipoic acid. Alpha-Lipon 300 STADA is a treatment for diabetic neuropathic pain developed by STADA Arzneimittel AG and currently sold through the company’s sales subsidiary Health Vision Enterprise Ltd. Available in China since 2005, Alpha-Lipon 300 STADA treats diabetic neuropathic pain through an antioxidant effect, which reduces overproduction of oxygen and normalizes glucose metabolism. More details... 



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital